Broliden K, Levén B, Arneborn M, Böttiger M
Department of Clinical Virology, Swedish Institute for Infectious Disease Control, Stockholm, Sweden.
Scand J Infect Dis. 1998;30(1):23-7. doi: 10.1080/003655498750002259.
In 1982, a 2-dose regimen was introduced in Sweden for the combined vaccination against measles, mumps and rubella (MMR) in children aged 18 months and 12 years. In 1993, blood samples from 378 12-year-old children, i.e. the first age-group receiving a MMR booster, were collected prior to and 2 months after the vaccination. 82% had a certificate of a previous measles (M) or MMR vaccination (group I). The remainder was classified as children with 'no documentation' (group II). In group I, 5 (1.5%) lacked demonstrable antibodies to measles prior to the booster; in group II this figure was 39%. The pre-booster antibody pattern was similar in M vaccinees and MMR vaccinees. After the vaccination, 1 of the 378 children was seronegative. In both groups, children with low pre-vaccination levels responded with a titre rise, in accordance with a similar study 6 years earlier.
1982年,瑞典采用了两剂次接种方案,对18个月和12岁儿童进行麻疹、腮腺炎和风疹联合疫苗(MMR)接种。1993年,在接种疫苗前和接种后2个月,采集了378名12岁儿童(即首个接种MMR加强针的年龄组)的血样。82%的儿童有既往麻疹(M)或MMR疫苗接种证明(第一组)。其余儿童被归类为“无接种记录”儿童(第二组)。在第一组中,5名儿童(1.5%)在加强针接种前缺乏可检测到的麻疹抗体;在第二组中,这一比例为39%。麻疹疫苗接种者和MMR疫苗接种者的加强针接种前抗体模式相似。接种疫苗后,378名儿童中有1名血清学检测呈阴性。与6年前的一项类似研究一致,在两组中,接种前抗体水平较低的儿童接种后抗体滴度均有所上升。